9th IMI call to be published soon

The JTI Innovative Medicines Initiative (IMI) will publish the 9th Call for proposals soon. The following topics are currently under consideration for inclusion in the call:
• WEBAE - Leveraging emerging technologies for pharmacovigilance;
• Developing innovative therapeutic interventions against physical frailty and sarcopenia (ITI-PF&S) as a prototype geriatric indication;
• Driving re-investment in R&D and responsible use of antibiotics (ND4BB topic 4);
• Clinical development of antibacterial agents for Gram-negative antibiotic resistant pathogens (ND4BB topic 5).
 
All information regarding IMI's 9th Call for for proposals is indicative and subject to change.

IMI will hold webinars on the Call topics as well as its rules and procedures. Registration is free but obligatory.

IMI is Europe's largest public-private partnership aiming to improve the drug development process by supporting a more efficient discovery and development of better and safer medicines for patients. It supports collaborative research projects and builds networks of industrial and academic experts in Europe that will boost innovation in healthcare. IMI's overall goal is to build a more collaborative ecosystem for pharmaceutical R&D in Europe and to speed up the development of more effective and safer medicines for patients. IMI is a Joint Undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA).